Comparison · NCT02826603-830f65d5
Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 12
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 12. Trial comparisons, record NCT02826603-830f65d5. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02826603-830f65d5
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.88 | 0.85 | 0.905 | wilson | |
| Risk in group 2 | 0.741 | 0.703 | 0.776 | wilson | |
| Risk difference, group 1 minus group 2 | 0.139 | 0.0932 | 0.184 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.19 | 1.12 | 1.26 | log | |
| Odds ratio, group 1 over group 2 | 2.56 | 1.86 | 3.53 | log | |
| Number needed to treat, for one more participant with the outcome on Secukinumab 300mg (2 x 150 mg) than on Ustekinumab 2 x 45mg or 90mg | 7.19 | 5.42 | 10.7 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Secukinumab 300mg (2 x 150 mg) | Secukinumab 300mg s.c. injection (2 150mg pre-fiilled syringes) | 484 | 550 | OG000 |
| Group 2 | Ustekinumab 2 x 45mg or 90mg | Ustekinumab s.c. 45 mg or 90 mg (depending on body weight) using 45mg pre-filled syringes (1 or 2 syringes) | 409 | 552 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 12
- Description
- Number of participants who achieved ≥ 75% reduction in PASI at Week 12 compared to baseline.
- Time frame
- Week 12
- Population
- FAS
Source ClinicalTrials.gov
Trial
- Title
- Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
- NCT number
- NCT02826603
- Phases
- PHASE3
- Conditions
- Plaque Psoriasis
- Interventions
- Secukinumab, Ustekinumab
- Lead sponsor
- Novartis Pharmaceuticals
- Results first posted
- 2019-07-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02826603?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02826603-830f65d5